rubella virus vaccine, live (Meruvax II)

Indications

vaccine-induced immunity to rubella

Contraindications

• hypersensitivity to neomycin
• pregnancy
• patients receiving immunosuppressive agents
• patients receiving radiation therapy

Caution:

• females should avoid pregnancy for 3 months afer vaccination
• defer vaccination for 3 months following plasma transfusions or administration of immune globulin or immunosuppressive drugs

Dosage

Injection: 1000 TCID50 of rubella (Wistar RA 27/3 Strain)

Adverse effects

• common (> 10%)
  • arthralgias
  • local tenderness & erythema
  • urticaria
  • rash
  • joint pain 1-10 weeks after vaccination, persisting 1-3 days
• less common (1-10%)
  • malaise, fever, headache, sore throat, lymphadenopathy
• uncommon (< 1%)
  • hypersensitivity, allergic reactions to vaccine, optic neuritis

Test interactions

• temporary suppression of TB skin test reactivity

More general terms

• live virus vaccine

Additional terms

• measles & rubella combined vaccine (M-R-VAX II)
• measles, mumps & rubella combined vaccine (MMR)
• rubella (German measles, 3rd disease)

Component of

• measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live
• measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live/varicella virus vaccine
• measles virus vaccine live attenuated/rubella virus vaccine live